{"product_id":"international-myeloma-society-workshop-on-assessment-of-response-and-progression-criteria-in-multiple-myeloma-2024","title":"International Myeloma Society Workshop on Assessment of Response and Progression Criteria in Multiple Myeloma 2024","description":"\u003ch3\u003eInternational Myeloma Society Workshop on Assessment of Response and Progression Criteria in Multiple Myeloma 2024\u003c\/h3\u003e\n\u003cstrong\u003eInclude: 9 videos, size: 4.04 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: hematologists \u0026amp; oncologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cbr\u003e\u003cbr\u003e​According to Leanne Richardson’s LinkedIn post, the IMS IMWG Multiple Myeloma Response Criteria Workshop took place in Paris in November 2024. The event focused on discussing and establishing new consensus criteria for clinical trials in multiple myeloma.​\u003cbr\u003e\u003cbr\u003eAlthough publicly available sources do not provide specific details about this workshop, previous workshops of the International Multiple Myeloma Working Group (IMWG) have made important contributions to standardizing response and progression criteria in the treatment of multiple myeloma. For example, international consensus response criteria for multiple myeloma were published at previous workshops, aiming to improve reporting and comparison of results between different clinical trials.​\u003cbr\u003eNature\u003cbr\u003e\u003cbr\u003eFor the most up-to-date and detailed information about the conference in Paris in November 2024, you should visit the official website of the International Multiple Myeloma Society (IMS) or contact them directly.\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cul\u003e\n\u003cli class=\"\" data-end=\"268\" data-start=\"164\"\u003e\n\u003cp class=\"\" data-end=\"268\" data-start=\"167\"\u003e\u003cstrong data-end=\"198\" data-start=\"167\"\u003eHematologists \u0026amp; Oncologists\u003c\/strong\u003e – Specialists involved in diagnosing and treating multiple myeloma.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"399\" data-start=\"269\"\u003e\n\u003cp class=\"\" data-end=\"399\" data-start=\"272\"\u003e\u003cstrong data-end=\"309\" data-start=\"272\"\u003eClinical Researchers \u0026amp; Scientists\u003c\/strong\u003e – Those working on new treatment strategies and response criteria for multiple myeloma.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"516\" data-start=\"400\"\u003e\n\u003cp class=\"\" data-end=\"516\" data-start=\"403\"\u003e\u003cstrong data-end=\"456\" data-start=\"403\"\u003ePharmaceutical \u0026amp; Biotech Industry Representatives\u003c\/strong\u003e – Companies developing new therapies and clinical trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"651\" data-start=\"517\"\u003e\n\u003cp class=\"\" data-end=\"651\" data-start=\"520\"\u003e\u003cstrong data-end=\"557\" data-start=\"520\"\u003eRegulatory Experts \u0026amp; Policymakers\u003c\/strong\u003e – Authorities involved in approving and standardizing response criteria in clinical trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"787\" data-start=\"652\"\u003e\n\u003cp class=\"\" data-end=\"787\" data-start=\"655\"\u003e\u003cstrong data-end=\"690\" data-start=\"655\"\u003eMedical Professionals \u0026amp; Fellows\u003c\/strong\u003e – Doctors and researchers looking to update their knowledge of response assessment in myeloma.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTopics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eConsensus Session – Response Criteria 2024.mp4\u003c\/li\u003e\n\u003cli\u003eSession 1 – Monoclonal protein assessments – Response Criteria 2024.mp4\u003c\/li\u003e\n\u003cli\u003eSession 2 – Bone marrow testing – Response Criteria 2024.mp4\u003c\/li\u003e\n\u003cli\u003eSession 3 – Peripheral blood – Response Criteria 2024.mp4\u003c\/li\u003e\n\u003cli\u003eSession 4 – Imaging for response assessment – Response Criteria 2024.mp4\u003c\/li\u003e\n\u003cli\u003eSession 5 – Response assessmet in smoldering – Response Criteria 2024.mp4\u003c\/li\u003e\n\u003cli\u003eSession 6 – Special situations – Response Criteria 2024.mp4\u003c\/li\u003e\n\u003cli\u003eSession 7 – Defining Progression – Response Criteria 2024.mp4\u003c\/li\u003e\n\u003cli\u003eSession 8 – Endpoints for clinical trial – Response Criteria 2024.mp4\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954473898082,"sku":"MED-AMB04085","price":40.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/International-Myeloma-Society-Workshop-on-Assessment-of-Response-and-Progression-Criteria-in-Multiple-Myeloma-2024-scaled-1.jpg?v=1779377411","url":"https:\/\/meducourse.com\/products\/international-myeloma-society-workshop-on-assessment-of-response-and-progression-criteria-in-multiple-myeloma-2024","provider":"Meducourse","version":"1.0","type":"link"}